Welcome to our dedicated page for Definitive Healthcare SEC filings (Ticker: DH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Definitive Healthcare Corp. reported that on March 30, 2026, director Jeff Haywood resigned from its Board of Directors and from the Board’s Human Capital Management and Compensation Committee, effective immediately. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
Following his departure, the Board size was reduced from nine members to eight members, and the Compensation Committee was reduced from three members to two members, reflecting his departure rather than adding a replacement director at this time.
Definitive Healthcare Corp. reported that Chief Executive Officer Kevin Coop had 175,524 shares of Class A common stock withheld by the company at $1.28 per share. These shares were retained by the issuer to cover Coop's tax withholding obligations tied to the vesting and settlement of previously reported restricted stock units, rather than being sold in an open-market transaction. After this tax-withholding disposition, Coop directly holds 5,116,465 shares of Definitive Healthcare common stock.
Graboske Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that EVP and Chief Data Officer Benjamin Graboske received a grant of 631,068 restricted stock units (RSUs) of Class A Common Stock. The award was recorded at a price of $0.00 per share, reflecting stock-based compensation rather than a cash purchase.
Each RSU represents a contingent right to receive one share of Class A Common Stock. According to the disclosure, 25% of these RSUs are scheduled to vest on March 1, 2027, with additional vesting at a rate of 6.25% thereafter. Following this grant, Graboske’s directly owned Class A Common Stock, including RSUs, totaled 1,312,026.654 shares.
Paris Jonathan reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that Chief Legal Officer Jonathan Paris received a grant of 481,505 restricted stock units, each representing one share of Class A common stock. According to the award terms, 25% of these RSUs vest on March 1, 2027, with 6.25% vesting every three months over the following three years, contingent on his continued service.
Heller Casey reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp.’s Chief Financial Officer, Casey Heller, reported an equity award of 733,301 restricted stock units (RSUs) tied to the company’s Class A common stock at a stated price of $0.00 per share. Each RSU represents a contingent right to receive one share.
According to the filing, 25% of these RSUs will vest on March 1, 2027, with an additional 6.25% vesting every three months over the following three years, as long as Heller remains in service. After this grant, Heller directly holds 2,007,322 shares or RSUs linked to Class A common stock.
Coop Kevin reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that Chief Executive Officer Kevin Coop received an equity award linked to 1,735,437 shares of Class A Common Stock in the form of restricted stock units. These RSUs vest 25% on March 1, 2027, then 6.25% every three months over the next three years, contingent on his continued service. Following this grant, Coop is reported as beneficially owning 5,291,989 shares of Class A Common Stock.
Definitive Healthcare Corp. executive chairman and 10% owner Jason Ronald Krantz reported an equity award. On February 24, 2026, he acquired 242,719 restricted stock units, each representing one share of Class A common stock, at no cost. These RSUs vest 100% on March 1, 2027, subject to his continued service. After this grant, he directly holds 1,258,758 shares. He also has indirect beneficial ownership of 450,000 shares through DH Holdings, formerly the Jason R. Krantz 2009 Trust, where he is the beneficiary.
Definitive Healthcare Corp. executive updates initial ownership report. EVP and Chief Data Officer Benjamin Graboske filed an amended Form 3 to reflect beneficial ownership of 4,045.654 shares of Class A Common Stock. A footnote explains these shares were mistakenly omitted from his original Form 3 and from two subsequent Forms 4.
Definitive Healthcare Corp. provides a SaaS healthcare data and analytics platform that supports commercial decisions across life sciences, providers and diversified healthcare customers. It serves approximately 2,330 customers and derives 96% of its revenue from subscriptions.
For the year ended December 31, 2025, the company reported a net loss of $199.3 million, an improvement from a net loss of $591.4 million in 2024. As of December 31, 2025, its workforce totaled 686 employees across the U.S., Europe and India. The report emphasizes intense competition, reliance on third‑party data, evolving privacy and security rules, macroeconomic pressures on customer spending, and execution risks around AI, innovation, acquisitions and restructuring.
Definitive Healthcare reported mixed 2025 results with improving profitability metrics but lower revenue. Q4 2025 revenue was $61.5 million, down 1% from $62.3 million in Q4 2024, while Adjusted EBITDA rose slightly to $18.0 million, or 29% of revenue, from $17.5 million and 28% a year earlier. Q4 net loss narrowed sharply to $17.1 million, including $19.5 million of goodwill impairment, compared with an $84.7 million loss including $97.1 million of impairment in Q4 2024.
For full year 2025, revenue was $241.5 million versus $252.2 million in 2024. Net loss was $199.3 million, including $196.1 million in goodwill impairment, improving from a $591.4 million loss with $688.9 million of impairment in 2024. Adjusted EBITDA was $70.4 million, or 29% of revenue, down from $79.1 million and a 31% margin. Operating cash flow reached $53.8 million and Unlevered Free Cash Flow was $54.9 million.
For 2026, the company guides revenue to $220.0–$226.0 million, Adjusted EBITDA to $53.0–$58.0 million with a 24–26% margin, and Adjusted Net Income to $21.0–$26.0 million, or $0.14–$0.17 per diluted share.